Relationship Between Intracranial Blood Flow and Peripheral Perfusion in Patients With Craniocerebral Injury
1 other identifier
observational
30
1 country
1
Brief Summary
Neurocritical care is a major branch in the field of critical care medicine, and more than 50% of the neurocritical care patients in the Tibet Autonomous Region People's Hospital (TARPH) are in neurocritical care, of which cranial damage accounts for about 30%, and paroxysmal sympathetic hyperexcitability syndrome (PSH) after traumatic brain injury(TBI)is a common complication, which affects the cardiorespiratory and cerebral functions to varying degrees, and optimizing the cerebral perfusion and oxygenation supply is the key point in the treatment of TIB, and the maintenance of the cerebral homeostasis and the functional homeostasis is currently an international hotspot for treatment. Maintaining cerebral homeostasis and body function homeostasis is an international hotspot in the treatment of TIB. This study intends to elaborate on the relationship between PSH and Intracranial blood flow in patients with TBI, as well as the effect of anti-stress treatment on Intracranial blood flow. Implementation Patients with brain injury admitted to our department from January 2021 to January 2022 were included. Non-invasive transcranial Doppler ultrasound was applied to measure cerebral blood flow, non-invasive local cerebral oxygen saturation monitor to measure local cerebral oxygen saturation, and an electroencephalography bispectrometer to measure BIS score to quantify the depth of sedation during the experimental process. Bedside ultrasound monitored the right heart function and lung water status, and the data of each monitoring index were monitored and recorded throughout the whole process, and the relationship between concomitant PSH and Intracranial blood flow in TBI patients was found according to the statistical analysis. Ultimately, to achieve the control of TBI complications and improve patient rescue. To expect to achieve the purpose of improving the prognosis of TBI patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
July 19, 2023
CompletedFirst Posted
Study publicly available on registry
August 30, 2023
CompletedAugust 30, 2023
August 1, 2023
1 year
July 19, 2023
August 23, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
intracranial blood flow
Mean intracranial middle cerebral artery blood flow velocity and pulsatility index measured using ultrasound Doppler in enrolled patients.
Day 1,Day 3,Day 5
Paroxysmal sympathetic excitation
Use of the Paroxysmal Sympathetic Nerve Score to assess paroxysmal sympathoexcitatory performance in patients.
Day 1,Day 3,Day 5
Study Arms (1)
cranial damage
Our study was a prospective observational study which included only a group of patients who were diagnosed with acute craniocerebral injury.
Eligibility Criteria
Definite craniocerebral injury, surgically treated and transferred to ICU.
You may qualify if:
- Craniocerebral injury patients;
- The middle cerebral artery blood flow spectrum can be clearly displayed with a bedside TCD;
You may not qualify if:
- Age Under 18 years;
- history of cardiovascular disease such as coronary artery disease, heart failure, or atrial fibrillation;
- presence of severe valvular disease or ejection fraction (EF) \<30%;
- chronic lung disease;
- chronic liver failure or renal insufficiency;
- persons with co-morbidities of malignant neoplasms;
- persons who had co-morbidities with acute and chronic infectious diseases prior to craniocerebral injuries;
- women who were pregnant and breastfeeding;
- history of psychiatric disorders;
- history of drug abuse or alcohol misuse;
- history of β-blockers;
- co-morbidities with spinal cord injuries; and persons who had died or been discharged from hospital within 1 week of hospitalization or who had not been able to obtain a clear image with ultrasonography.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wei Du
Beijing, Beijing Municipality, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 19, 2023
First Posted
August 30, 2023
Study Start
January 1, 2021
Primary Completion
January 1, 2022
Study Completion
January 1, 2022
Last Updated
August 30, 2023
Record last verified: 2023-08